CyBorD Plus Daratumumab

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

What will happen during the trial?

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
53 patients (estimated)
Sponsors
Memorial Sloan Kettering Cancer Center
Collaborators
Janssen Pharmaceuticals
Tags
Monoclonal Antibody, CD38, Quadruplet Therapy
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1781
NCT Identifier
NCT06083922

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.